Unknown PHASE4 INTERVENTIONAL 2-arm NCT00870402

Aldosterone in Diabetic Nephropathy (ALDODN)

Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy.

Sponsor: Universidad de los Andes, Chile

Conditions Diabetic Nephropathy

Interventions Placebo Spironolactone

Updated 6 times since 2017 Last updated: Mar 25, 2009 Started: Mar 31, 2009 Primary completion: Dec 31, 2009 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetic Nephropathy and is currently ongoing. Universidad de los Andes, Chile leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jan 2021 — Oct 2021 [monthly]

Unknown Status PHASE4
Jan 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jan 2019 [monthly]

Unknown Status PHASE4

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universidad de los Andes, Chile

Data source: Universidad de los Andes, Chile

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santiago, Chile